trending Market Intelligence /marketintelligence/en/news-insights/trending/EPCNEiMprFEOFD8cwgim5g2 content esgSubNav
In This List

G&E Herbal Biotechnology Q1 loss narrows YOY


Gold - Geopolitical tensions and inflation remain key drivers


Lithium and Cobalt - Softer demand weighs on prices


Street Talk | Episode 94: Recessionary fears in ’22 overblown, Fed could overtighten


Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

G&E Herbal Biotechnology Q1 loss narrows YOY

G&E Herbal Biotechnology Co. Ltd. said its first-quarter normalized net income amounted to a loss of 3 Taiwan cents per share, compared with a loss of 5 cents per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was a loss of NT$1.4 million, compared with a loss of NT$3.0 million in the year-earlier period.

The normalized profit margin increased to negative 15.3% from negative 55.6% in the year-earlier period.

Total revenue rose 70.5% on an annual basis to NT$9.3 million from NT$5.5 million, and total operating expenses rose 24.5% year over year to NT$18.2 million from NT$14.6 million.

Reported net income came to a loss of NT$2.7 million, or a loss of 5 cents per share, compared to a loss of NT$4.0 million, or a loss of 7 cents per share, in the prior-year period.

As of May 13, US$1 was equivalent to NT$32.68.